Jazz Pharmaceuticals Shares Outstanding 2007-2019 | JAZZ

Jazz Pharmaceuticals shares outstanding history from 2007 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Jazz Pharmaceuticals shares outstanding for the quarter ending September 30, 2019 were 0.057B, a 7.14% decline year-over-year.
  • Jazz Pharmaceuticals 2018 shares outstanding were 0.061B, a 0.16% decline from 2017.
  • Jazz Pharmaceuticals 2017 shares outstanding were 0.061B, a 0.89% decline from 2016.
  • Jazz Pharmaceuticals 2016 shares outstanding were 0.062B, a 1.85% decline from 2015.
Jazz Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2018 61
2017 61
2016 62
2015 63
2014 63
2013 62
2012 60
2011 47
2010 39
2009 30
2008 26
2007 14
2006 0
2005 0
Jazz Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q3 2019 57
Q2 2019 57
Q1 2019 58
Q4 2018 61
Q3 2018 62
Q2 2018 61
Q1 2018 61
Q4 2017 61
Q3 2017 61
Q2 2017 61
Q1 2017 61
Q4 2016 62
Q3 2016 62
Q2 2016 62
Q1 2016 63
Q4 2015 63
Q3 2015 63
Q2 2015 63
Q1 2015 63
Q4 2014 63
Q3 2014 63
Q2 2014 62
Q1 2014 59
Q4 2013 62
Q3 2013 62
Q2 2013 62
Q1 2013 62
Q4 2012 60
Q3 2012 61
Q2 2012 61
Q1 2012 58
Q4 2011 47
Q3 2011 47
Q2 2011 47
Q1 2011 46
Q4 2010 39
Q3 2010 42
Q2 2010 35
Q1 2010 35
Q4 2009 30
Q3 2009 31
Q2 2009 29
Q1 2009 29
Q4 2008 26
Q3 2008 27
Q2 2008 24
Q1 2008 24
Q4 2007 14
Q3 2007 24
Q2 2007 8
Q1 2007 0
Q4 2006
Q3 2006 13
Q2 2006 0
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $7.968B $1.891B
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $68.471B 39.61
Takeda Pharmaceutical (TAK) Japan $60.597B 10.74
Astellas Pharma (ALPMY) Japan $32.582B 16.27
Eisai (ESALY) Japan $23.185B 44.70
Merck (MKGAF) Germany $17.215B 23.49
Grifols, S.A (GRFS) Spain $16.941B 22.20
Neurocrine Biosciences (NBIX) United States $9.626B 267.44
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Catalent (CTLT) United States $8.851B 36.42
Ionis Pharmaceuticals (IONS) United States $8.458B 17.13
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
IPSEN SA ADR (IPSEY) France $6.104B 0.00
Orion OYJ (ORINY) Finland $5.871B 0.00
STADA ARZNEIMI (STDAF) Germany $5.543B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.540B 0.00
Hypermarcas (HYPMY) Brazil $5.461B 16.61
United Therapeutics (UTHR) United States $4.572B 0.00
Evotec AG (EVTCY) Germany $4.261B 68.88
Arrowhead Pharmaceuticals (ARWR) United States $4.195B 77.87
Nektar Therapeutics (NKTR) United States $4.069B 0.00
FibroGen (FGEN) United States $3.977B 116.87
PTC Therapeutics (PTCT) United States $3.559B 0.00
Sage Therapeutics (SAGE) United States $3.528B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.790B 11.29
ChemoCentryx (CCXI) United States $2.786B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.092B 0.00
Pacira Pharmaceuticals (PCRX) United States $2.086B 61.72
Xencor (XNCR) United States $2.070B 62.91
Ironwood Pharmaceuticals (IRWD) United States $1.891B 23.19
Heron Therapeutics (HRTX) United States $1.891B 0.00
Tilray (TLRY) Canada $1.748B 0.00
USANA Health Sciences (USNA) United States $1.626B 17.00
Corcept Therapeutics (CORT) United States $1.525B 18.53
CLINIGEN GP (CLIGF) United Kingdom $1.506B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.469B 10.02
Zogenix (ZGNX) United States $1.424B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.424B 0.00
Endo (ENDP) Ireland $1.395B 2.56
Portola Pharmaceuticals (PTLA) United States $1.062B 0.00
Akebia Therapeutics (AKBA) United States $1.041B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.034B 32.03
Dermira (DERM) United States $1.022B 0.00
ImmunoGen (IMGN) United States $1.018B 0.00
Karyopharm Therapeutics (KPTI) United States $0.966B 0.00
Radius Health (RDUS) United States $0.922B 0.00
Aerie Pharmaceuticals (AERI) United States $0.901B 0.00
Collegium Pharmaceutical (COLL) United States $0.775B 0.00
TherapeuticsMD (TXMD) United States $0.673B 0.00
Flexion Therapeutics (FLXN) United States $0.631B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.543B 0.00
Molecular Templates (MTEM) United States $0.536B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.492B 59.63
BioSpecifics Technologies Corp (BSTC) United States $0.478B 20.59
Ardelyx (ARDX) United States $0.474B 0.00
Translate Bio (TBIO) United States $0.471B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.444B 0.00
Innate Pharma SA (IPHYF) France $0.442B 0.00
Organogenesis Holdings (ORGO) United States $0.431B 0.00
Recro Pharma (REPH) United States $0.420B 0.00
Indivior (INVVY) United States $0.417B 2.48
BioCryst Pharmaceuticals (BCRX) United States $0.415B 0.00
Siga Technologies (SIGA) United States $0.393B 8.98
DURECT (DRRX) United States $0.377B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.372B 0.00
Harpoon Therapeutics (HARP) United States $0.370B 0.00
Lannett Co Inc (LCI) United States $0.367B 5.91
Calithera Biosciences (CALA) United States $0.366B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.356B 0.00
Rafael Holdings (RFL) United States $0.349B 0.00
Concert Pharmaceuticals (CNCE) United States $0.322B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.320B 0.00
OptiNose (OPTN) United States $0.285B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.272B 0.00
KalVista Pharmaceuticals (KALV) United States $0.270B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.267B 0.00
Ocular Therapeutix (OCUL) United States $0.250B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.228B 0.00
MEI Pharma (MEIP) United States $0.227B 0.00
IMV INC (IMV) Canada $0.213B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.205B 0.00
Nature's Sunshine Products (NATR) United States $0.205B 35.27
Taiwan Liposome (TLC) Taiwan $0.200B 0.00
Jounce Therapeutics (JNCE) United States $0.194B 2.60
AcelRx Pharmaceuticals (ACRX) United States $0.127B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.125B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.124B 0.00
CannTrust Holdings (CTST) Canada $0.119B 0.00
Otonomy (OTIC) United States $0.114B 0.00
Aquestive Therapeutics (AQST) United States $0.110B 0.00
Redhill Biopharma (RDHL) Israel $0.110B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.108B 0.00
Xeris Pharmaceuticals (XERS) United States $0.108B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.097B 0.00
CV Sciences (CVSI) United States $0.094B 0.00
Champions Oncology (CSBR) United States $0.084B 0.00
MediWound (MDWD) Israel $0.081B 0.00
Neos Therapeutics (NEOS) United States $0.078B 0.00
Infinity Pharmaceuticals (INFI) United States $0.078B 0.00
Onconova Therapeutics (ONTX) United States $0.074B 0.00
CTI BioPharma (CTIC) United States $0.072B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.070B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.068B 20.23
RENEURON GP (RNUGF) United Kingdom $0.059B 0.00
SCYNEXIS (SCYX) United States $0.057B 0.00
Aclaris Therapeutics (ACRS) United States $0.056B 0.00
Nivalis Therapeutics (ALPN) United States $0.056B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.053B 0.00
VAXART, INC (VXRT) United States $0.052B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.052B 0.00
Natural Alternatives (NAII) United States $0.052B 23.44
Dipexium Pharmaceuticals (PLXP) United States $0.047B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.047B 0.00
PolarityTE (PTE) United States $0.046B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.043B 0.00
Mannatechorporated (MTEX) United States $0.038B 0.00
Iterum Therapeutics (ITRM) Ireland $0.037B 0.00
Jaguar Animal Health (JAGX) United States $0.035B 0.00
ElectroCore (ECOR) United States $0.031B 0.00
Biomerica (BMRA) United States $0.028B 0.00
PharmAthene (ALT) United States $0.027B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.027B 0.00
China SXT Pharmaceuticals (SXTC) China $0.024B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Bio-Path Holdings (BPTH) United States $0.019B 0.00
Regulus Therapeutics (RGLS) United States $0.018B 0.00
Cardiome Pharma (CORV) Canada $0.017B 0.00
Shineco (TYHT) China $0.015B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.015B 0.00
Heat Biologics (HTBX) United States $0.014B 0.00
HANCOCK JAFFE (HJLI) United States $0.013B 0.00
Novan (NOVN) United States $0.013B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Lipocine (LPCN) United States $0.012B 0.00
Vical (BBI) United States $0.010B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.008B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.008B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
RXi Pharmaceuticals (PHIO) United States $0.002B 0.00
Midatech Pharma (MTP) United Kingdom $0.002B 0.00